化合物BX795 T1830

Product Introduction
Bioactivity


英文名: BX795

描述: BX795 是一种选择性PDK1抑制剂，也是相对特异性的TBK1和IKKɛ 抑制剂。它抑制 S6K1，Akt，PKCδ 和 GSK3β 的磷酸化，可调节自噬。

细胞实验: Cells seeded at a low density (1,500–3,000 cells/well, 0.1 mL/well, 96-well plates) are incubated overnight. Compound treatments are made by adding 10 μL/well of the compound in 1% dimethyl sulfoxide and growth medium (final concentration of dimethyl sulfoxide, 0.1%), followed by brief shaking. Treated cells are incubated for 72 hours, and viability is measured by the addition of 10 μL of the metabolic dye WST-1. The WST-1 signal is read in a plate reader at 450 nm, and a no cell, or zero time cell, background is subtracted to calculate the net signal. Results are reported as the average ± S.E. of two or more replicates.(Only for Reference)

激酶实验: Kinase assays: PDK1 is assayed in a direct kinase assay and a coupled assay format measuring PDK1- and PtdIns-3,4-P2-mediated activation of AKT2. For the coupled assay, the final assay mixture (60 μL) contained: 15 mM MOPS, pH 7.2, 1 mg/mL bovine serum albumin, 18 mM β-glycerol phosphate, 0.7 mM dithiothreitol, 3 mM EGTA, 10 mM MgOAc, 7.5 μM ATP, 0.2 μCi of [γ-33P]ATP, 7.5 μM biotinylated peptide substrate (biotin-ARRRDGGGAQPFRPRAATF), 0.5 μL of PtdIns-3,4-P2-containing phospholipid vesicles, 60 pg of purified recombinant human PDK1, and 172 ng of purified recombinant human AKT2. After incubation for 2 h at room temperature, the biotin-labeled peptide is captured from 10 μl of the assay mixture on streptavidin-coated SPA beads, and product formation is measured by scintillation proximity in a Wallac MicroBeta counter. The product formed is proportional to the time of incubation and to the amount of PDK1 and inactive AKT2 added. PDK1 is added at suboptimal levels so that the assay could sensitively detect inhibitors of AKT2 activation as well as direct inhibitors of PDK1 or AKT2. To measure PDK1 activity directly, the final assay mixture (60 μL) contained 50 mM Tris-HCl, pH 7.5, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% β-mercaptoethanol, 1 mg/mL bovine serum albumin, 10 mM MgOAc, 10 μM ATP, 0.2 μCi of [γ-33P]ATP, 7.5 μM substrate peptide (H2N-ARRRGVTTKTFCGT), and 60 ng of purified recombinant human PDK1. After 4 h at room temperature, we add 25 mM EDTA and spotted a portion of the reaction mixture on Whatman P81 phosphocellulose paper. The filter paper is washed three times with 0.75% phosphoric acid and once with acetone. After drying, the filter-bound labeled peptide is quantified using a Fuji phosphorimager.

体内活性: BX795（1 μM）对以下酪氨酸蛋白激酶无抑制作用: 肝配蛋白受体A2和B3,Bruton's酪氨酸激酶,Syk和FGFR1。但BX795对抑制血管内皮生长因子受体的抑制效果低于TBK1。BX795对IRF3 Ser396位点磷酸化（TBK1-催化）的抑制作用随着ATP浓度上升而下降,意味着BX795是ATP竞争性抑制剂。BX795也抑制NUAK1,MARK1/2/4,VEGFR和MLK1/2/3,IC50分别为5,55,53,19,157,50,46和42 nM。BX795对IRF3依赖的基因转录具有抑制作用。BX795对巨噬细胞的IFN-β分泌也有抑制作用。BX795阻断IKKε和TBK1调节的IRF3激活,并对IFN-β的产量有抑制效果。BX795对TBK1/IKKε的抑制不会引起p38α MAPK和JNK1/2的激活。BX795可抑制聚(I:C)处理后IRF3在核中的积累。BX795不影响脂多糖刺激的p70核糖体S6激酶1Thr229位点的磷酸化,该位点是PDK1的作用靶点。BX795不影响NFκB依赖的基因转录激活（由IKKα/β复合体或脂多糖、聚(I:C)、IL-1α或TNFα促进）。BX795对IL-1α或TNFα刺激的MEFs有效,并阻断p38α MAPKJ和NK1/2磷酸化。

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 59.2 mg/mL (100 mM)
Ethanol : 59.2 mg/mL (100 mM)


关键字: IKK | Inhibitor | I kappa B kinase | inhibit | BX795 | BX-795 | IκB kinase | PDK-1 | BX 795 | Autophagy

相关产品: Bay 11-7085 | GSK8612 | BAY-985 | Cudraflavone B | TBK1-IN-1 | MRT67307 | Vinpocetine | Cyclo(L-Pro-L-Val) | Resveratrol | PS-1145

相关库: PI3K-AKT-mTOR Compound Library | HIF-1 Signaling Pathway Compound Library | Inhibitor Library | Kinase Inhibitor Library | Highly Selective Inhibitor Library | Anti-Cancer Active Compound Library | Tyrosine Kinase Inhibitor Library | Metabolism Compound Library | NO PAINS Compound Library | Bioactive Compound Library

化合物BX795 T1830信息由TargetMol中国为您提供，如您想了解更多关于化合物BX795 T1830报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途